Interview with Carlo Ciapparelli, General Manager, IMS Health Belgium
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
Address: Medialaan 38, 1800 Vilvoorde,Belgium
Tel: +32 2 627 32 11
Web: http://www.imshealth.com/portal/site/ims
A market leader for more than 55 years, we blend industry expertise and advanced technology to deliver the most accurate perspectives and in-depth analytics on healthcare dynamics. Actionable insights, powered by superior information assets, are tuned to our clients’ precise requirements
We continuously innovate to keep pace with a global healthcare environment that is increasingly complex and interdependent. Whether our clients are decision makers in life sciences, payers, providers or policymakers, our analytical, commercial services and consulting capabilities are key to competitive advantage — and to achieving high-quality, cost-effective healthcare.
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without…
Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar…
Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder…
After reaching revenues of EUR 2.323 billion in the first six months of 2019, UCB announced on December 18 that it will build an innovative multi-product biological manufacturing facility on…
The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted by MSD in collaboration with the European Cancer Patient Coalition (ECPC),…
Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of…
Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing…
One of NNE Pharmaplan’s latest exciting news is that last year you established offices to accommodate your existing customers in Belgium. What were the strategic motivations for establishing a presence…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mrs van der Kamp, you launched your career as a strategy consultant however, since then you have moved into the pharmaceutical industry by joining Novartis where you quickly worked your…
With an expenditure of more than 10% of GDP on health, Belgium maintains one of the world’s leading healthcare systems. That said, could you please comment on the current state…
See our Cookie Privacy Policy Here
